|
|
Article: Series D Adds $20M To Propel Koronis' Viral Extinction Drug.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
A firm developing drugs based on the concept of using a virus' own replication process against it, Koronis Pharmaceuticals Inc. raised $20 million in a Series D round to support mid-stage trials with its lead small-molecule therapeutic in HIV.
The financing should "fund about six quarters of development," said Donald Elmer, managing partner at Pacific Horizon Ventures and Koronis' interim CEO, including two planned Phase IIa studies of oral KP-1461 in HIV patients, as well as final formulation work and long-term animal toxicity studies of the drug.
Earlier this week, the Seattle-based company started enrolling up to 32 patients in ...